Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy.

Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy.

OBJECTIVE: To report our clinical experience and 5-year prostate-specific antigen (PSA) relapse-free survival rate for early-stage prostate cancer after (125)I low-dose-rate prostate brachytherapy. PATIENTS AND METHODS: In all, 300 patients were treated between March 1999 and April 2003, and follow...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Khaksar, S, Laing, R, Henderson, A, Sooriakumaran, P, Lovell, D, Langley, SE
Format:	Journal article
Sprache:	English
Veröffentlicht:	2006

Ähnliche Einträge

Urinary morbidity after 125I brachytherapy of the prostate.
von: Henderson, A, et al.
Veröffentlicht: (2004)

Novel prostate brachytherapy technique: improved dosimetric and clinical outcome.
von: Nobes, J, et al.
Veröffentlicht: (2008)

Novel prostate brachytherapy technique: improved dosimetric and clinical outcome.
von: Nobes, J, et al.
Veröffentlicht: (2008)

Brachytherapy: the surgeon's perspective.
von: Henderson, A, et al.
Veröffentlicht: (2004)

Gleason scoring varies among pathologists and this affects clinical risk in patients with prostate cancer.
von: Sooriakumaran, P, et al.
Veröffentlicht: (2005)

The development of computer assisted permanent Brachytherapy for prostate cancer
von: Shi, Xiaoming.
Veröffentlicht: (2008)

COX-2 inhibition: a possible role in the management of prostate cancer?
von: Sooriakumaran, P, et al.
Veröffentlicht: (2007)

Management of prostate cancer. Part 3: metastatic disease.
von: Shah, J, et al.
Veröffentlicht: (2006)

Improved seed-based MR and CT image registration for prostate brachytherapy
von: Kim, Elizabeth S. (Elizabeth Seon-wha), 1979-
Veröffentlicht: (2005)

A novel method of obtaining prostate tissue for gene expression profiling.
von: Sooriakumaran, P, et al.
Veröffentlicht: (2009)

A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer.
von: Sooriakumaran, P, et al.
Veröffentlicht: (2009)

Management of prostate cancer. Part 2: localized and locally advanced disease.
von: Sooriakumaran, P, et al.
Veröffentlicht: (2006)

Patched 1 expression correlates with biochemical relapse in high-risk prostate cancer patients
von: Gonnissen, A, et al.
Veröffentlicht: (2018)

A blinded, randomized controlled trial of neo-adjuvant celecoxib in patients with early prostate cancer.
von: Sooriakumaran, P, et al.
Veröffentlicht: (2006)

A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer.
von: Sooriakumaran, P, et al.
Veröffentlicht: (2009)

Survival and PSA relapse data after hypofiractionated radiotherapy for early stage prostate cancer
von: Law, A, et al.
Veröffentlicht: (2007)

A blinded, randomised controlled trial of neo-adjuvant Celecoxib in patients with localised prostate cancer
von: Sooriakumaran, P, et al.
Veröffentlicht: (2007)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
von: Lilja, H, et al.
Veröffentlicht: (2008)

Biology of prostate-specific antigen
von: Lilja, H
Veröffentlicht: (2003)

Biology of prostate-specific antigen.
von: Lilja, H
Veröffentlicht: (2003)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
von: Vickers, A, et al.
Veröffentlicht: (2010)

Apples and oranges: comparison of treatment methods for prostate cancer using biochemical recurrence as an endpoint.
von: Sooriakumaran, P, et al.
Veröffentlicht: (2012)

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.
von: Botchorishvili, G, et al.
Veröffentlicht: (2009)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy.
von: Avery, K, et al.
Veröffentlicht: (2012)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy
von: Avery, K, et al.
Veröffentlicht: (2012)

Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
von: Haese, A, et al.
Veröffentlicht: (2004)

Uji diagnostik prostate spesific antigen (PSA) pada keganasan prostat
von: , DAHESIHDEWI, Andaru, et al.
Veröffentlicht: (2002)

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
von: Bangma, C, et al.
Veröffentlicht: (2010)

Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
von: Brindle, L, et al.
Veröffentlicht: (2006)

[Isoforms of free prostate-specific antigen]
von: Haese, A, et al.
Veröffentlicht: (2004)

Isoforms of free prostate-specific antigen
von: Haese, A, et al.
Veröffentlicht: (2004)

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
von: Vickers, A, et al.
Veröffentlicht: (2011)

Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
von: Denmeade, SR, et al.
Veröffentlicht: (2003)

Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.
von: Evans-Axelsson, S, et al.
Veröffentlicht: (2012)

Management of prostate cancer. Part 1: chemoprevention.
von: Sooriakumaran, P
Veröffentlicht: (2006)

Prostate volume and its correlation with histopathological outcomes in prostate cancer.
von: Sooriakumaran, P, et al.
Veröffentlicht: (2011)

Updates on molecular and biochemical development and progression of prostate cancer
von: Fahmy, Omar, et al.
Veröffentlicht: (2021)

Lifestyle, biochemical, and genetic risk factors for prostate cancer
von: Byrne, K
Veröffentlicht: (2017)

The usefulness of prostate specific antigen density in prostate cancer detection: a Malaysian perspective
von: Shanggar, K., et al.
Veröffentlicht: (2010)

Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
von: Denmeade, SR, et al.
Veröffentlicht: (2003)